| Name: | Description: | Size: | Format: | |
|---|---|---|---|---|
| 1 MB | Adobe PDF |
Advisor(s)
Abstract(s)
Myopia is the most common ocular disorder worldwide with an increasing prevalence over the past few decades. It is a refractive error associated with excessive growth of the eyeball. Individuals with myopia, especially high myopia, are prone to develop sight-threatening complications. Currently, atropine is the only drug that is used to slow myopia progression in clinical practice. However, there are still areas of uncertainty such as treatment strategy, optimal concentration when considering the risk-benefit ratio, and active treatment period. Since the prevalence of myopia is much higher in Asian countries, most of the research on myopia control has been conducted in Asia. Data on the efficacy and tolerability of atropine eye drops in the non-Asian population remains limited. In this review, we summarize the results of published clinical trials on the effectiveness and tolerability of atropine eye drops for myopia control in non-Asian regions. The efficacy was evaluated by the mean change in spherical equivalent (SE) or axial length (AL). The tolerability of atropine eye drops was analyzed based on patients' complaints and adverse events. The results of this review suggest that 0.01% atropine eye drops are effective in non-Asian regions achieving fewer side effects compared to 0.5% concentration.
Description
Keywords
Ophthalmology Myopia Atropine eye drops Myopia control Myopia progression Myopia treatment
Pedagogical Context
Citation
Simonaviciute D, Grzybowski A, Lança C, Pang CP, Gelzinis A, Zemaitiene R. The effectiveness and tolerability of atropine eye drops for myopia control in non-Asian regions. J Clin Med. 2023;12(6):2314.